Abstract
The main indication for androgen therapy is the treatment of androgen deficiency in hypogonadal men. Since such androgen replacement therapy usually involves life-long administration of testosterone, it is desirable that testosterone formulations be long-acting. The primary goal of androgen replacement therapy is to replicate the physiological actions of endogenous testosterone. This requires not just rectification of deficient androgen levels but also avoiding either supranormal or excessively fluctuating testosterone levels. Thus the practical intent of androgen replacement therapy is to maintain stable, physiological testosterone levels for prolonged periods. The pharmacological properties of testosterone, notably its rapid metabolic inactivation by the liver, have dictated that the achievement of such prolonged androgenic effects requires the development of depot, sustained-release testosterone formulations (Wilson 1980). Nevertheless, even 50 years after the entry of testosterone into the clinical armamentarium (Hamilton 1937; Foss 1939) the quest for a safe, effective, inexpensive, convenient, long-acting androgen preparation with reproducible, zero-order release profile remains an important challenge not yet met. One of the oldest testosterone formulations is the subdermal implant of testosterone pellets which provide stable testosterone levels for at least 4 months after a single implantation (Cantrill et al. 1984; Conway et al. 1988). Curiously this cheap and effective treatment modality has been neglected for decades despite its many advantages for androgen replacement therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson DC (1974) Sex-hormone-binding globulin. Clin Endocrinol 3: 69–96
Bishop PMF, Folley SJ (1951) Absorption of hormone implants. Lancet 2: 229–232
Biskind GR, Escamilla RF, Lisser H (1941) Implantation of testosterone compounds in cases of male eunuchoidism. J Clin Endocrinol 1: 38–49
Boylan LM, Conway AJ, Handelsman DJ (1989) Dose and duration characteristics of testosterone pellets in men. Proc Endocrine Society of Australia Annual Scientific Meeting, 32: 34
Burris AS, Ewing LL, Sherins RJ (1988) Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril 50: 493–497
Cantrill J, Dewis P, Large D, Newman M, Anderson DC (1984) Which testosterone replacement therapy? Clin Endocrinol 21: 97–107
Conway AJ, Boylan LM, Howe C, Ross G, Handelsman DJ (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11: 247–264
Deansley R, Parkes AS (1937) Factors influencing effectiveness of administered hormones. Proc Royal Soc London series B 124: 279–298
Deansley R, Parkes AS (1938) Further experiments on the administration of hormones by the subcutaneous implantation of tablets. Lancet 2: 606–608
Deslypere JP, Vermeulen A (1984) Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. 59: 955–962
Dewis P, Newman M, Ratcliffe WA, Anderson DC (1986) Does testosterone affect the normal menstrual cycle? Clin Endocrinol 24: 515–521
Diaz-Sanchez V, Garza-Flores J, Larrea F, Richards E, Ulloa-Aguirre A, Veayra F (1989) Absorption of dihydrotestosterone ( DHT) after its intramuscular administration. Fertil Steril 51: 493–497
Dorfman RI, Hamilton JB (1941) Rate of excretion of urinary androgens after administration of testosterone by various routes. J Clin Endocrinol 1: 352–358
Eidelsberg J, Ornstein EA (1940) Observations on the continued use of male sex hormone over long periods of time. Endocrinology 26: 46–53
Emmens W (1941) Rate of absorption of androgens and estrogens in free and esterified form from subcutaneously implanted pellets. Endocrinology 28: 633–642
Forbes TR (1941) Absorption of pellets of crystalline testosterone, testosterone propionate, methyl testosterone, progesterone, desoxycorticosterone and stilbestrol implanted in the rat. Endocrinology 32: 70–76
Foss GL (1939) Clinical administration of androgens. Lancet 1: 502–504
Foss GL(1942) Implantation of sex hormone tablets in man. J Endocrinol 3: 107–117
Frey H, Aakvag A, Saanum D, Falch J (1979) Bioavailability of oral testosterone in males. Eur J Clin Pharmacol 16: 345–349
Gandy HM (1977) Androgens. In: Fuchs F, Klopper A (eds) Endocrinology of pregnancy, 2nd edn. Harper & Row, Hagerstown, pp 123–156
Gardner FH, Besa EC (1983) Physiologic mechanisms and the hematopoeitic effects of the androstanes and their derivatives. Curr Top Hematol 4: 123–195
Groopman JE, Molina JM, Scadden DT (1989) Hematopoietic growth factors: biology and clinical applications. New Engl J Med 321: 1449–1459
Hamilton JB (1937) Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 21: 649–654
Hamilton JB, Dorfman RI (1939) Influence of the vehicle upon the length and strength of the action of male hormone substance, testosterone propionate. Endocrinology 24: 711–719
Handelsman DJ, Conway AJ, Boylan LM, Turtle JR (1984) Testicular function in potential sperm donors: normal ranges and the effects of smoking and varicocele. Int J Androl 7: 369–382
Handelsman DJ, Staraj S (1985) Testicular size: the effects of aging, malnutrition and illness. J Androl 6: 144–151
Handelsman DJ, Conway AJ, Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71: 216–222
Hellman L, Bradlow HL, Frazell EL, Gallagher TF (1956) Tracer studies of the absorption and fate of steroid hormones in man. J Clin Invest 35: 1033–1044
Howard JE, Vest SA (1939) Clinical experiments with male sex hormones. II. Further observations on testosterone propionate in adult hypogonadism, and preliminary report on the implantation of testosterone. Am J Med Sci 198: 823–837
Kochakian CD (1976) Metabolic effects. In: Kochakian CD (ed) Anabolic-androgenic steroids. Springer, Berlin, pp 5–72 (Handbook of experimental pharmacology, vol 43 )
Knuth UA, Nieschlag E (1987) Endocrine approaches to male fertility control. In: Burger HG (ed) Clinical endocrinology and metabolism. Bailliere Tindall, London, 1: 113–131
Loeser AA (1940) Subcutaneous implantation of female and male hormone in tablet form in women. Br Med J 479–482
Mooradian AD, Morley JE, Korenman SG (1987) Biological actions of androgens. Endocr Rev 8: 1–28
Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N (1985) Anemia in chronic renal failure. Acta Endocrinol (Kbh) suppl 271: 80–86
Nieschlag E, Mauss J, Coert A, Kicovic P (1975) Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Kbh) 79: 366–374
Nieschlag E, Cuppers HJ, Wickings EJ (1977) Influence of sex, testicular development and liver function on the bioavailability of oral testosterone. Eur J Clin Invest 7: 145–147
Parkes AS (1938) Effective absorption of hormones. Br Med J 371–373
Petra P, Stanczyk FZ, Namkung PC, Fritz MA, Novy ML (1985) Direct effect of sex steroid-binding protein ( SBP) of plasma on the metabolic clearance rate of testosterone in the rhesus macaque. J Steroid Biochem 22: 739–746
Reiter T (1963) Testosterone implantation: a clinical study of 240 implantations in ageing males. J Am Geriat Soc 11: 540–550
Rommerts FFG (1988) How much androgen is required for maintenance of spermatogenesis? J Endocr 116: 7–9
Southren AL, Gordon GG, Tochimoto S (1968) Further studies of factors affecting metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab 28: 1105–112
Swyer GIM (1953) Effects of testosterone implants in men with defective spematogenesis. Br Med J 1080–1081
Thom MH, Collins WP, Studd JWW (1981) Hormonal profiles in postmenopausal women after therapy with subcutaneous implants. Br J Obstet Gynecol 88: 426–433
Thorn GW, Firor WM (1940) Desoxycorticosterone acetate therapy in Addisons disease. J Am Med Assoc 114: 2517–2525
Vermeulen AL, Verdonck L, van der Straeten M, Orie N (1969) Capacity of testosterone binding globulin in human plasma and influence of specific binding of testosterone on its metabolic clearance rate. J Clin Endocrinol Metab 29: 1470–1480
Vest SA, Howard JE (1939) Clinical experiments with androgens. IV: a method of implantation of crystalline testosterone. J Am Med Assoc 113: 1869–1872
von Schoultz B, Carlstrom K (1989) On the regulation of sex-hormone-binding globulin–a challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem 32: 327–334
Weinbauer GF, Khurshid S, Fingscheidt U, Nieschlag E (1989) Sustained inhibition of sperm production and inhibin secretion induced by a gonadotropin-releasing hormone antagonist and delayed testosterone substitution in non-human primates ( Macca fascicularis ). J Endocrinol 123: 303–310
Wilson JD Griffin JE (1980) The use and misuse of androgens. Metabolism 29: 1278–1295
Ying SY (1988) Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 9: 267–293
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Handelsman, D.J. (1990). Pharmacology of testosterone pellet implants. In: Nieschlag, E., Behre, H.M. (eds) Testosterone. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00814-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-662-00814-0_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-00816-4
Online ISBN: 978-3-662-00814-0
eBook Packages: Springer Book Archive